VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

Phase 1 Completed 42 enrolled Pediatric Brain Tumor Consortium National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of VNP40101M in treating young patients with recurrent, progressive, or refractory primary brain tumors.

Timeline

Start: 2005-02
Primary completion: 2006-10
Completion: 2008-02

Publications

Results Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15;14(4):1124-30. doi: 10.1158/1078-0432.CCR-07-4242.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	laromustine	Other / unclassified	20 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	30 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	45 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	60 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	78 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	103 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	137 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	182 mg/m2	Intravenous
Subject	laromustine	Other / unclassified	242 mg/m2	Intravenous

VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

Summary

Timeline

Publications

Drugs

Indications